The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.
Gravity Diagnostics provides testing for toxicology, pharmacogenetics, infectious and upper respiratory diseases, blood diagnostics, and COVID-19.
Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.
The diagnostics startup is developing a testing platform that uses digital imaging and signal processing for pathogen identification and susceptibility determination.
Demand remains low, but lab stakeholders said the industry is significantly better prepared to meet a spike in H5N1 testing ...
NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...
Imagene's AI-based multigene panel for predicting non-small cell lung cancer biomarkers from biopsy images will be combined with Tempus' real-world data.
The digital pathology software developer is raising funding that would help it to increase its headcount and support its Aiosyn Mitosis Breast application.
The Foundation Medicine next-generation sequencing-based panels use Fulgent's technology platform and will analyze genes associated with hereditary cancers.
Qiagen said the intellectual property in question covers technologies used in its QuantiFeron latent tuberculosis assays.
Cubit Diagnostics announced on Tuesday that it has been awarded $2.6 million by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Tech program. The funding will enable the ...
Revvity Sees Possible Path to Higher Growth Rates in 2025 While Firm's Q4 Dx Revenues Rise 4 Percent
NEW YORK – Revvity said Friday that it is on the path back to higher growth rates following two years of slower growth, although company officials said that they are tempering expectations for 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results